H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Immunology D-index 101 Citations 49,842 355 World Ranking 252 National Ranking 22
Medicine D-index 115 Citations 59,215 504 World Ranking 1959 National Ranking 193

Research.com Recognitions

Awards & Achievements

Fellow of The Academy of Medical Sciences, United Kingdom

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Asthma
  • Disease

His primary areas of investigation include Asthma, Internal medicine, Immunology, Sputum and Eosinophil. The study incorporates disciplines such as Eosinophilia, Respiratory disease and Randomized controlled trial in addition to Asthma. His Internal medicine research integrates issues from Gastroenterology and Placebo.

The various areas that Ian D. Pavord examines in his Immunology study include Bronchoalveolar lavage and Eosinophilic. His Sputum study integrates concerns from other disciplines, such as Prostaglandin and Surgery. The concepts of his Eosinophil study are interwoven with issues in Inhalation and Anti-asthmatic Agent.

His most cited work include:

  • Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. (1443 citations)
  • Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma (1404 citations)
  • Cluster analysis and clinical asthma phenotypes. (1360 citations)

What are the main themes of his work throughout his whole career to date?

Asthma, Internal medicine, Immunology, Sputum and COPD are his primary areas of study. His studies deal with areas such as Randomized controlled trial, Airway and Intensive care medicine as well as Asthma. The Internal medicine study combines topics in areas such as Gastroenterology and Placebo.

The study of Immunology is intertwined with the study of Eosinophilic in a number of ways. His Sputum study combines topics in areas such as Respiratory disease and Spirometry. Ian D. Pavord has included themes like Biomarker and Pulmonary disease in his COPD study.

He most often published in these fields:

  • Asthma (47.23%)
  • Internal medicine (38.92%)
  • Immunology (27.95%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (38.92%)
  • Asthma (47.23%)
  • Dupilumab (4.94%)

In recent papers he was focusing on the following fields of study:

His main research concerns Internal medicine, Asthma, Dupilumab, In patient and Intensive care medicine. The study incorporates disciplines such as Gastroenterology and Placebo in addition to Internal medicine. Ian D. Pavord interconnects Post-hoc analysis and Eosinophil in the investigation of issues within Placebo.

His biological study focuses on Exhaled nitric oxide. His Intensive care medicine research includes elements of Inhaled corticosteroids, Precision medicine and MEDLINE. In his work, Eosinophilic and Immunology is strongly intertwined with Sputum, which is a subfield of Mepolizumab.

Between 2018 and 2021, his most popular works were:

  • Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019 (472 citations)
  • Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma (123 citations)
  • Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. (87 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Asthma
  • Disease

Ian D. Pavord mostly deals with Asthma, Internal medicine, Intensive care medicine, MEDLINE and Exhaled nitric oxide. His study in Asthma focuses on Asthma Control Questionnaire in particular. His study connects Placebo and Internal medicine.

His biological study spans a wide range of topics, including Precision medicine, Inhalation, Guideline, Inhaled corticosteroids and Asthma control. His Exhaled nitric oxide study combines topics from a wide range of disciplines, such as Gastroenterology and Inhaler. Within one scientific family, Ian D. Pavord focuses on topics pertaining to Immunology under COPD, and may sometimes address concerns connected to Fibrocyte and Prostaglandin D2.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

Ruth H Green;Christopher E Brightling;Susan McKenna;Beverley Hargadon.
The Lancet (2002)

1979 Citations

Cluster analysis and clinical asthma phenotypes.

Pranab Haldar;Ian D. Pavord;Dominic E. Shaw;Michael A. Berry.
American Journal of Respiratory and Critical Care Medicine (2008)

1944 Citations

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

Pranabashis Haldar;Christopher E. Brightling;Beverley Hargadon;Sumit Gupta.
The New England Journal of Medicine (2009)

1835 Citations

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Ian D Pavord;Stephanie Korn;Peter Howarth;Eugene R Bleecker.
The Lancet (2012)

1795 Citations

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

Hector G. Ortega;Mark C. Liu;Ian D. Pavord;Guy G. Brusselle.
The New England Journal of Medicine (2014)

1551 Citations

Mast-Cell Infiltration of Airway Smooth Muscle in Asthma

Christopher E. Brightling;Peter Bradding;Fiona A. Symon;Stephen T. Holgate.
The New England Journal of Medicine (2002)

1406 Citations

An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice.

Helen K. Reddel;D. Robin Taylor;Eric D. Bateman;Louis-Philippe Boulet.
American Journal of Respiratory and Critical Care Medicine (2009)

1251 Citations

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

Elisabeth H. Bel;Sally E. Wenzel;Philip J. Thompson;Charlene M. Prazma.
The New England Journal of Medicine (2014)

1134 Citations

British guideline on the management of asthma: A national clinical guideline

Graham Douglas;Bernard Higgins;Neil Barnes;Anne Boyter.
Thorax (2008)

1122 Citations

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

R H Green;C E Brightling;G Woltmann;D Parker.
Thorax (2002)

968 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Ian D. Pavord

Peter G. Gibson

Peter G. Gibson

University of Newcastle Australia

Publications: 317

Christopher E. Brightling

Christopher E. Brightling

University of Leicester

Publications: 237

Kian Fan Chung

Kian Fan Chung

National Institutes of Health

Publications: 179

Peter J. Barnes

Peter J. Barnes

Imperial College London

Publications: 168

Guy Brusselle

Guy Brusselle

Ghent University Hospital

Publications: 154

David Price

David Price

University of Aberdeen

Publications: 153

Jean Bousquet

Jean Bousquet

Inserm : Institut national de la santé et de la recherche médicale

Publications: 152

Dave Singh

Dave Singh

University of Manchester

Publications: 151

Andrew Bush

Andrew Bush

National Institutes of Health

Publications: 145

Sally E. Wenzel

Sally E. Wenzel

University of Pittsburgh

Publications: 129

Anne B. Chang

Anne B. Chang

Boston Children's Hospital

Publications: 122

Claus Bachert

Claus Bachert

Ghent University

Publications: 118

Marc Miravitlles

Marc Miravitlles

Instituto de Salud Carlos III

Publications: 118

Giorgio Walter Canonica

Giorgio Walter Canonica

Humanitas University

Publications: 117

Paul M. O'Byrne

Paul M. O'Byrne

McMaster University

Publications: 115

Peter J. Sterk

Peter J. Sterk

University of Amsterdam

Publications: 104

Something went wrong. Please try again later.